Wednesday 10th January 2018
|Text too small?|
London-listed veterinary drugs maker Dechra Pharmaceuticals has bought local distributor RxVet for an undisclosed sum, continuing its expansion in Australasia over the past couple of years.
Northwich, UK-based Dechra completed its acquisition of Kapiti-based RxVet in December, and is keeping founders Peter Blaikie and Nick Gorman on to "help to increase market share and build Dechra's presence in the region," it said in a statement to the London stock exchange. The pharmaceuticals firm didn't say how much it paid, but said the Kiwi firm generated sales of $1.4 million in the March 2017 financial year, of which about half came from its own products.
RxVet has distributed Dechra products since it was set up in 2010 and offers a range of products for vets to treat dogs, cats and horses. The company touts its strong links to the local industry on its website, with Blaikie named president of the New Zealand Veterinary Association last year, and Gorman a 15-year veteran in animal pharmaceuticals having previously held a senior role at Intervet Schering Plow.
The acquisition is small for Dechra, which generated a profit of 28.6 million British pounds on revenue of 359.3 million pounds in the 2017 financial year, and follows an expansion into Australasia with a 2016 purchase of Apex Laboratories for A$55 million. That deal gave Dechra direct access to Australia's pet market which had previously been serviced through partners, and allowed it to build a "base from which to support and build Dechra’s expansion in the Australasian and Asian regions", it said in its 2017 annual report.
The RxVet bolt-on acquisition was noted in a trading update to the London stock exchange, which said Dechra increased revenue on a constant currency basis 11 percent in the final six months of 2017.
The shares rose 2 percent to 20.46 pounds overnight.
No comments yet
NZ dollar rises on optimism for China-US trade deal
Steel & Tube recovery to include $5.6M of 2nd-half cost savings
Open Country challenges validity of Fonterra's 2018 milk price
Guest night growth slows; overseas visitors spent less time in North Island
Nib NZ first-half earnings slide 30% as claims outpace policy growth
Customer satisfaction in NZ banks rises despite Australian scandals
Perky services sector in Janary soothes fears over cooling economy
PFI doubles 2018 profit on valuation gains, underlying earnings fall short
Steel & Tube turnaround continues with 49% jump in first-half net profit
February 18th Morning Report